Insiders Are Buying Cannabis Stocks

You’re reading a copy of this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve as well as links to the week’s most important news.

Subscribe to receive our free weekly newsletter in your inbox each Sunday morning.


In a bull market for stocks, cannabis stocks are sitting it out. Despite the recent rally, they are down 13.9% this year as measured by the NCV Global Cannabis Stock Index. We have discussed all year how cannabis stocks are cheap relative to how they have been valued historically. Investors looking for a sign that folks are interested don’t see that in the trading volumes, which remain low. There is, however, evidence that insiders see the valuations as low.

Green Thumb Industries (OTC: GTBIF) (CSE: GTII) revealed in its 10-Q that it had quickly followed through on its early-September announcement of a potential 10 million share repurchase. It bought 2.5 million shares at $9.96 during September. It’s so rare to see companies buying their own stock in the cannabis sector. After the quarter ended, two senior executives each sold 500K shares at $10 privately to a qualified institutional buyer. While many get alarmed by insider selling, we don’t see this as a negative development.

We have been looking for the strategic investors that have been investing in Canadian LPs to potentially buy them at the much-lower prices. British American Tobacco fell short of buying Organigram (NASDAQ: OGI) (TSX: OGI) when it announced an increased stake ahead in early November. The company will be investing C$125 million in three tranches at C$3.22, a much lower price than its initial investment but quite higher than the current price. The cash-rich debt-free company will become more cash-rich.

One company that has seen a lot of buying by several different executives and directors recently is SHF Holdings (NASDAQ: SHFS), the parent of Safe Harbor Financial. We called this a potential bear market bargain in mid-May when it was at $0.43. SEC filings over the past week or so seem to have driven the stock up to $1.00. The stock now trades at 2.4X tangible book value, and the$41.7 million enterprise value is about 8X the projected 2024 adjusted EBITDA by a single analyst. Investors should note that the ratio of current assets to current liabilities is a very low 0.5X as of the end of Q3. Not the bargain it was!

TerrAscend (OTC: TSNDF) (NEO: TSND) has rallied 38% this year, and insiders have been been buying it the whole time. Most recently, JW Asset Management added 10K shares at $1.5855 on 12/6. This brings its holdings to an impressive 90.4 million shares. Of this amount, Jason Wild, the company’s Executive Chairman, owns 2.7 million. At year-end 2022, JW Asset Management owned 88.5 million shares with Wild owning 2.2 million.

These parties that are buying the cannabis stocks don’t know the answer to the big question of 280E going away. Again, 280E would be wiped out if cannabis were to be rescheduled from Schedule 1 to Schedule 3, which the Department of Health and Human Services has recommended to the DEA. It’s nice to see this buying, but we aren’t excited enough by it to change our cautious view.

New Cannabis Ventures publishes curated articles as well as exclusive news. Here is some of the most interesting business content from this week:


October Cannabis Sales Dip

To get real-time updates download our free mobile app for Android or Apple devices, like our Facebook page, or follow Alan on Twitter. Share and discover industry news with like-minded people on the largest cannabis investor and entrepreneur group on LinkedIn.

Use the suite of professionally managed NCV Cannabis Stock Indices to monitor the performance of publicly-traded cannabis companies within the day or over longer time-frames. In addition to the comprehensive Global Cannabis Stock Index, we offer the Canadian Cannabis LP Index, the American Cannabis Operator Index and the Ancillary Cannabis Index.

View the Public Cannabis Company Revenue & Income Tracker, which ranks the top revenue producing cannabis stocks.

Stay on top of some of the most important communications from public companies by viewing upcoming cannabis investor earnings conference calls.

Discover upcoming new listings with the curated Cannabis Stock IPOs and New Issues Tracker.


Alan & Joel

Exclusive article by Alan Brochstein, CFA
Alan Brochstein, CFA
Based in Houston, Alan leverages his experience as founder of online community 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email

Get Our Sunday Newsletter